Robert B. Greenblatt

Improved diagnostic procedures and use of a new steroidal agent, danazol (Danocrine), should reduce the need for surgical intervention in fibrocystic breast disease. Thermography, a non-invasive procedure that may be used with impunity, may…

Three groups of women with benign breast disease were treated with danazol for 3 to 6 months. Doses of 100 mg per day were given to 40 patients, 200 mg to 55, and 400 mg to 35. The age range of the patients was 20 to 48 years. The patients …

Danazol, an interesting pharmacologic steroid 'in search of a disease', was first used by my group in the management of endometriosis because of the marked anti-endometrial effects found during clinical trials. The results in alleviating dy…

Benign breast disease, aside from fibroadenomas and intraductal papillomas, frequently responds favorably to hormonal therapy. Although the use of estrogen, androgens, and progestogens often proves useful, danazol, in our hands, was found m…

Danazol, an impeded androgen with moderate antigonadotropin properties, was administered to 58 patients with a variety of benign breast disorders. The disturbances were present from 3 months to 20 years; the ages ranged from 21 to 50 years.…

To the Editor:— A plea was made, "let's be honest with the pill." Regretfully, the manner in which the data were presented left room for wholly unwarranted conclusions. Thus, unintentionally perhaps, they were less than honest with "the pil…

ONLY in recent years has an understanding of the physiology of functional uterine bleeding afforded a rational approach to successful therapy. Not until twenty-three years ago, when Allen (1) postulated that menstruation was due to cyclic r…